Comparative Pharmacology
Head-to-head clinical analysis: ADVIL versus MECLOMEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL versus MECLOMEN.
ADVIL vs MECLOMEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby reducing pain, fever, and inflammation.
Meclomen (meclofenamate) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This results in anti-inflammatory, analgesic, and antipyretic effects.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day (OTC). For prescription: 400-800 mg orally 3-4 times daily; maximum 3200 mg/day.
50-100 mg orally every 6-8 hours; maximum 400 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life in adults; prolonged in overdose or renal impairment: up to 8-12 hours)
Terminal elimination half-life: 0.8–1.1 hours for meclofenamic acid; 2–4 hours for metabolites. Short half-life requires frequent dosing (e.g., every 6–8 hours) for sustained effect.
Renal: ~95% (hepatic metabolites and conjugates, <1% unchanged); biliary/fecal: ~5%
Renal (approximately 70% as metabolites, <5% unchanged); fecal/biliary (approximately 30% as metabolites).
Category C
Category C
NSAID
NSAID